EquityZen Growth Technology Fund LLC - Series 1831
Raised
$298K
Investors
10
Min Invest
$5,019
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 1831 is a Delaware pooled investment fund vehicle filed by EquityZen Advisors LLC and Philip Haslett, raising $298K from 10 investors under Rule 506(b) and Section 3(c)(1). The offering has a $5K minimum investment and is part of EquityZen's pre-IPO access platform, which operates over 1,800 related series vehicles.
This pre-IPO fund follows the typical EquityZen model: a sub-$1M raise with accessible minimums ($5K) under the private 506(b) exemption and 3(c)(1) investment company exclusion. The structure and scale are consistent with single-company SPVs designed to pool capital for access to shares of private growth-stage companies.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Philip Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
